Current and Future Perspectives for Levofloxacin in Severe Pseudomonas aeruginosa Infections

REFERENCES

• Bonfiglio G, Carciotto V, Russo G, et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. J Antimicrob Chemother 1998; 41 (2): 307–10.
   PubMed Web of Science ®Google Scholar
• Gianoglio S, Capuzzo R, Molinari MP, Debbia EA Epidemiologia dei microrganismi gram-negativi e gram-positivi isolati nel 1997 in un grande nosocomio nazionale e valu-tazione della sensibilita agli antibiotici di P. aeruginosa. GIM-MOC 1999; III(A): SA7-SA17.
   Google Scholar
• Periti P, Nicoletti P, De Gaudio AR, et al. La chemio-therapia antimicrobica nelle Unita' di Terapia Intensiva. Farmaci Terapia 2000; XVII-3/4: 161-74.
   Google Scholar
• Nicastri E, Martini L, Larosa M, Petrosillo N, Ippolito G for the Inf-Nos Study Group. Multicentre Prevalence Survey of Nosocomial Infections in Italy. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Sept 27-30, 2002 San Diego, USA. 333.
   Google Scholar
• Logroscino CD, Penza 0, Locicero S, et al. Community-acquired pneumonia in adults: a multicentric observational AIPO study. Monaldi Archives for Chest Disease 1999; 54 (1): 11–7.
   PubMedGoogle Scholar
• Sanguinetti CM, De Benedetto F, Miragliotta G. Bacterial agents of lower respiratory tract infections (LRTIs), beta-lactamase production, and resistance to antibiotics in elderly people. DEDALO Study Group. Int J Antimicrob Agents 2000; 16 (4): 467–71.
   PubMed Web of Science ®Google Scholar
• Hancock R. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacte-ria. Clin Infect Dis 1998; 27 (Suppl 1): S93–S99.
   PubMed Web of Science ®Google Scholar
• Segatore B, Setacci D, Perilli M et al. Italian survey on the comparative levofloxacin susceptibility in 334 clinical iso-lates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43 (2): 428-31.
   Google Scholar
• Spanu T, Ardito AF, Velardi G, Siddu A, Fadda G. Attivita' in vitro di beta-lattamici, aminoglicosidi e ciprofloxaci-na nei confronti di 515 ceppi di Pseudomonas aeruginosa isolati dalle secrezioni respiratorie di pazienti ospedalizzati. Microbiologia Medica 1999; 14 (2) Suppl 1: S1-S11.
   Google Scholar
• Bonfiglio G. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy 2001; 47 (4): 239-42.
   Google Scholar
• Gesu GP, Marchetti F, Piccoli L, Cavallero A, Levofloxacin and ciprofloxacin in vitro activity on 4003 bacte-rial clinical isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 2003; 47 (2): 816–9.
   PubMed Web of Science ®Google Scholar
• Morrissey I, Hoshino K, Sato K et al. Mechanism of differential activities of ofloxacin enantiomers. Antimicrob Agents Chemother 1996; 40 (8): 1775–84.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Cruciani M, Bassetti D. Levofloxacina. Farmaci 2000; Suppl. 24-5(11).
   Google Scholar
• Simpson KL, Markam A Ofloxacin otic solution: a review of its use in the management of ear infections. Drugs 1999; 58 (3): 509–31.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Broggio R, Marchetti F, Di Modugno E. Susceptibility of bacterial respiratory pathogens collected in Italy in 1998-1999 to levofloxacin (LVX) and ciprofloxacin (CIP). GIMMOC 2000; IV C&M 3; abs. 26.
   Google Scholar
• Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and mol-ecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001; 32 (2): S146–S155.
   PubMedGoogle Scholar
• Sahm DF, Critchley IA, Kelly II, et al. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveil-lance. Antimicrob Agents Chemother 2001; 45: 267–74.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, and Levofloxacin Surveillance GroupS. In abstract of the 22nd International Congress of Chemotherapy. International Society of Chemotherapy, Stockolm, Sweden. Abstr. P27.035
   Google Scholar
• Sahm D, Draghi D, Master D, et al. Pseudomonas aeruginosa Antimicrobial Resistance Update: U.S. Resistance Trends from 1998 to 2001. 42nd ICAAC Abstracts, American Society for Microbiology, September 27-30, 2002, San Diego, CA, p. 91
   Google Scholar
• Drago L, De Vecchi E, Mombelli B, Nicola L, Valli M Gismondo MR. Activity of levofloxacin and ciprofloxacin against urinary pathogens. J Antimicrob Chemother 2001; 48: 37–45.
   Google Scholar
• Cosentini R, Blasi F, Tarsia P, Grugnetti A, Popescu-Janu A. Levofloxacin vs ciprofloxacin susceptibility of gram negative bacteria obtained from respiratory tract specimens. The European Respiratory Society Annual Congress. Berlin, Germany, 22-26 September 2000, Abstract 924.
   Google Scholar
• Corsini V, Castagna B, Marchetti F Campa M. In vitro activity of levofloxacin and ciprofloxacin on bacterial clinical isolates collected from liver-transplanted recipients. 3rd European Congress of Chemotherapy, Madrid, Spain, May 7-10, 2000 p 334
   Google Scholar
• Ruggeri P, Crisafulli E, Giacobbe G, Girbino G. Bacterial agents of community acquired lower respiratory tract infections: observational study on antimicrobial drugs suscepti-bility. The European Respiratory Society Annual Congress. Stockholm, Sweden, 14-18 September 2002. Abstract 321.
   Google Scholar
• Golini G, Favari F, Marchetti F, Fontana R. In vitro bac-tericidal activity of levofloxacin and ciprofloxacin on clinical isolates obtained from patients with cystic fibrosis Clin Microbiol Infect 2001; 7 (1): 162.
   Google Scholar
• Garlaschi L, Cariani L, Colombo R, et al. Attivita' in vitro di levofloxacina e ciprofloxacina verso batter gram nega-tivi non fermentanti di isolamento clinico. Atti del XXXIII Congresso Nazionale della Societa Italiana di Microbiologia. Bari, 23-26 giugno 2001.Abstract 32.
   Google Scholar
• Segatore B, Setacci D, Perilli M, Franceschini N, Marchetti F, Amicosante G. Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa. Int J Antimicrob Agents 2000; 13 (3): 223–6.
   PubMed Web of Science ®Google Scholar
• Drago L, De Vecchi E, Nicola L, Valli M, Marchetti M, Gismondo MR. Comparative bactericidal activity of fluoro-quinolones against clinical isolates resistant to fluoro-quinolones. J Chemother 2003; 15,2: 118–23.
   PubMed Web of Science ®Google Scholar
• Visalli M, Jacobs M, Appelbaum P. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome and meropenem against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology. Antimicrob Agents Chemother 1998; 42 (4): 953–5.
   PubMed Web of Science ®Google Scholar
• Flynn CM, Johnson DM, Jones RN. In vitro efficacy of levofloxacin alone or in combination tested against multi-resis-tant Pseudomonas aeruginosa strains. J Chemother 1996; 8 (6): 411–5.
   PubMed Web of Science ®Google Scholar
• Burgess DS, Nathisuwan S. Cefepime, piperacillin/ tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microb Infect Dis 2002; 44 (1): 35–41.
   PubMed Web of Science ®Google Scholar
• Pendland SL, Messick CR, Jung R. In vitro synergy test-ing of levofloxacin, ofloxacin, and ciprofloxacin in combina-tion with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002; 42 (1): 75–8.
   PubMed Web of Science ®Google Scholar
• Isemberg H, Alperstein P, France K. In vitro activity of ciprofloxacin, levofloxacin and trovafloxacin alone and in com-bination with beta-lactams against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkolderia cepacia. Diagn Microbiol Infect Dis 1999; 33: 81–86.
   PubMed Web of Science ®Google Scholar
• Gilbert DN, Moellering RC, Sande eds. The Sanford guide to antimicrobial therapy thirty-second edition 2002. Antimicrobial Therapy Inc. VT, USA.
   Google Scholar
• Piccoli L., Marchetti F, Guerrini M, Di Modugno E. Attivita' in vitro di ceftazidime in associazione a levofloxacina o amikacina nei confronti di batter Gram-negativi non fer-mentanti. Atti del 21°Congresso Nazionale della Societa' Italiana di Chemioterapia Firenze, 2-5 dicembre 2001: Abstr A16 p.164.
   Google Scholar
• M'Zali F, Hawkey P, Thomson C. The comparative in vitro activity of ciprofloxacin and levofloxacin against clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2000; 6 Suppl. 1: 91.
   Google Scholar
• Gillespie T, Masterton R. The in vitro selection of resis-tant mutants by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antiinfective Drug and Chemotherapy 1998; 16 Suppl 1: 81.
   Google Scholar
• Drlica K, Schmitz F Therapeutic options in a era of decreasing antimicrobial susceptibility. J Chemother 2002; 14 Suppl 2: 5–12.
   PubMedGoogle Scholar
• Poole K. Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. Antimicrob Agents Chemother 2000; 44 (9): 2233–41.
   PubMed Web of Science ®Google Scholar
• Kohler T, Michea-Hamzehpour, Plesiat P, Kahr AL, Pechere JC. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41 (11): 2540–3.
   PubMed Web of Science ®Google Scholar
• Jalal S, Ciofu 0, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2000; 44 (3): 710-2.
   Google Scholar
• Hansen G, Blondeau J, Drlica K, Zhao X. Evaluation of ciprofloxacin and levofloxacin by mutation prevention concen-tration against 119 isolates of Pseudomonas aeruginosa. 41nd ICAAC Abstracts, American Society for Microbiology, December 16-19, 2001, 2002, Chicago, IL, p 180.
   Google Scholar
• Hansen G., Drlica K, Blondeau J. Comparison of propensity of ciprofloxacin and levofloxacin to select fluoro-quinolone resistant Pseudomonas aeruginosa using a mutant selection curve. 42nd ICAAC Abstracts, American Society for Microbiology, September 27-30, 2002, San Diego, CA, p 155.
   Google Scholar
• Blondeau J, Hansen G. Mutant prevention concentra-tion for quinolone and non quinolone antimicrobial agents against clinical isolates of Pseudomonas aeruginosa and the effect of antibiotic combinations. Int J Antimicrob Agents 2001: 17 Suppl 1: S121.
   Google Scholar
• Blondeau J, Zhao X, Hansen G, Drlica K. Mutant pre-vention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45 (2): 433–8.
   PubMed Web of Science ®Google Scholar
• Madaras-Kelly K, Ostergaard B, Hovde L, Rotschafer J. Twenty-four-huor area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40 (3): 627–32.
   PubMed Web of Science ®Google Scholar
• Eron LJ, Harvey L, Hixon DL, Poretz DM. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother 1985; 28 (2): 308–10.
   PubMed Web of Science ®Google Scholar
• Klesel N, Geweniger KH, Koletzki P et al. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. J Antimicrob Chemother 1995; 35 (6): 805-19.
   Google Scholar
• Soejima R, Kawane H, Okimoto N, Umeki S, Sumi M, Tamada S. Comparative study of levofloxacin and ofloxacin in bacterial pneumonia by the double-blind method. Chemotherapy 1992; 40 (3): 121–46.
   Google Scholar
• Kloss G, Krauss H. Klinische Prüfung mit Ofloxacin. FAC 1986; 5: 877–85.
   Google Scholar
• Giamarellou H, Galanakis N, Dendrinos C, Stefanou J, Daphnis E, Daikos GK. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 1986; 5 (2): 232–5.
   PubMedGoogle Scholar
• Yagel SK, Barrett JF, Amaratunga DJ, Frosco MB. In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia. Antimicrob Agents Chemother 1996; 40 (12): 2894–7.
   PubMed Web of Science ®Google Scholar
• Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998; 279 (2): 125–9.
   PubMed Web of Science ®Google Scholar
• MacGowan A, Wootton M, Holt A. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 1999; 43: 345–9.
   PubMed Web of Science ®Google Scholar
• Noviello S, Ianniello F, Leone S, Esposito S. Comparative in vitro bacteriostatic and bactericidal activity of levofloxacin and ciprofloxacin against urinary tract pathogens determined by MIC. MBC, Time-kill curves and bactericidal index analysis. Infezioni Medicina 2002; 10 (2): 100–6.
   Google Scholar
• Wiedemann B. Levofloxacin compensates with pharma-cokinetics for less favourable pharmacodynamics towards Pseudomonas aeruginosa compared to ciprofloxacin. Clin Microbiol Infect 2002; 8 (1): 25.
   Google Scholar
• Naber C, Hammer H, Kinzig-Schippers M, Sorgel F, Naber KG. Urinary excretion and bactericidal activity of lev-ofloxacin versus ciprofloxacin in healthy volunteers after a sin-gle oral dose of 500 mg. 9th International Congress on Infectious Diseases. Buenos Aires, 10-13 April, 2000; 19.
   Google Scholar
• Novelli A. Symposium: La terapia antibiotica di associ-azione nelle infezioni gravi. Concetti di farmacocinetica-dinam-ica della combinazione. Atti del 21°Congresso Nazionale della Societa' Italiana di Chemioterapia 2001 p. 85.
   Google Scholar
• Sanguinetti CM, Fina P and the LEVT03 Study Group. Intravenous vs oral treatment of community acquired pneumo-nia (cap) with levofloxacin (1): a randomized multicentre, national study. 3rd International Meeting on the Therapy of Infections. Florence, 4-6 December 2000: p. 144.
   Google Scholar
• Furlanut M, Brollo L, Lugatti E, et al. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 2003; 51: 101–6.
   PubMed Web of Science ®Google Scholar
• Cadeo B, Villani P, Viale P et al. Pharmacodynamics of levofloxacin in the treatment of infective endocarditis. Clin Microbiol Infect 2002; 8 Suppl 1: 26
   PubMed Web of Science ®Google Scholar
• Pea F, Milaneschi R, Baraldo M, Lugatti E, Talmassons G, Furlanut M. Ciprofloxacin Disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. Ther Drug Monit 2000; 22 (4): 386–91.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Andreetta V, Felici A, Marchetti F. Comparison of ceftazidime, levofloxacin and amikacin alone or in combination in a murine septicemia model by Pseudomonas aeruginosa. 42 International Conference on Antimicrobial Agents and Chemotherapy, San Diego 27-30 September, 2002 p 46.
   Google Scholar
• Craig W. Pharmacokinetic/pharmacodynamic proper-ties of antimicrobial combinations for Gram-negative bacteria. Pharmacotherapy 2001; 21 Suppl 11 Pt 3: 337.
   Google Scholar
• De Abate CA, Russel M, McElvaine P, Faris H, Upchurch J, Grunemberg RN. Safety and efficacy of oral lev-ofloxacin vs cefuroxime axetil. Respir Care 1997; 42: 206–13.
   Google Scholar
• Shah PM, Maesen FP, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treat-ment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother 1999; 43 (4): 529–39.
   PubMed Web of Science ®Google Scholar
• Tsang KW, Chan WM, Ho PL, Chan K, Lam WK, Ip MS. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. Eur Respr J 1999; 14 (5): 1206–9.
   PubMed Web of Science ®Google Scholar
• Soejima R, Atsushi S. The first comparative study with levofloxacin—a double blind comparative study of gatifloxacin, a new fluoroquinolone, and levofloxacin in chronic respiratory tract infections. J Antimicrob Chemother 1999; 44 Suppl A: 141.
   Google Scholar
• Ishii T, Takayama M. Phase III clinical study of lev-ofloxacin in otitis media and otitis externa. Chemotherapy 1992; 40: 334–51.
   Google Scholar
• Kawada Y. Inclusion criteria for acute uncomplicated cystitis. Infection 1992; 20 (3): 143–4.
   PubMedGoogle Scholar
• Nichols RL, Smith JW, Gentry LO, et al. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J 1997; 90 (12): 1193–2000.
   PubMed Web of Science ®Google Scholar
• Kahn J, Wiesinger B, Williams R, Corrado M, Dornseif B. Levaqin in the treatment of chronic osteomyelitis. Clin Infect Dis 1998; 27 (4): 945.
   Google Scholar
• Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother 2000; 44 (1): 164–6.
   PubMed Web of Science ®Google Scholar
• Geddes A, Thaler M, Schonwald S, Harkonen M, Jacobs F, Nowotny I. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. J Antimicrob Chemother 1999; 44 (6): 799–810.
   PubMed Web of Science ®Google Scholar
• Kahn J, Wiesinger B, Dross M, et al. Multicenter, ran-domized, open label study comparing safety and efficacy of levofloxacin with that of imipenem/cilastatin in treatment of nosocomial pneumonia. Abstract Book of the 10th International Congress on Infectious Diseases, Singapore, March 2002, p 149.
   Google Scholar
• Kahn J, Oross M, Tennemberg A, Wiesinger B. Levofloxacin in the treatment of P. aeruginosa in patients with nosocomial pneumonia. Clin Microbiol Infect 2002; 8 (1): 335.
   Google Scholar
• http://www.levaquin.com/news/11-05-02.html by Ortho-McNeil Pharmaceuticals, USA.
   Google Scholar